NASDAQ:RKLB • US7731211089
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for ROCKET LAB CORP (RKLB).
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2026-04-07 | Citizens | Upgrade | Market Perform -> Market Outperform |
| 2026-04-01 | Wells Fargo | Initiate | Equal-Weight |
| 2026-03-19 | Clear Street | Initiate | Buy |
| 2026-03-13 | Cantor Fitzgerald | Reiterate | Overweight -> Overweight |
| 2026-02-27 | Citizens | Reiterate | Market Perform -> Market Perform |
| 2026-02-27 | Cantor Fitzgerald | Maintains | Overweight -> Overweight |
| 2026-01-20 | Goldman Sachs | Maintains | Neutral -> Neutral |
| 2026-01-20 | B of A Securities | Maintains | Buy -> Buy |
| 2026-01-16 | Morgan Stanley | Upgrade | Equal-Weight -> Overweight |
| 2026-01-15 | Keybanc | Downgrade | Overweight -> Sector Weight |
| 2025-12-23 | Needham | Maintains | Buy -> Buy |
| 2025-12-22 | Stifel | Maintains | Buy -> Buy |
| 2025-11-25 | Needham | Reiterate | Buy -> Buy |
| 2025-11-19 | B of A Securities | Maintains | Buy -> Buy |
| 2025-11-12 | Needham | Maintains | Buy -> Buy |
| 2025-11-12 | Morgan Stanley | Maintains | Equal-Weight -> Equal-Weight |
| 2025-11-11 | Stifel | Reiterate | Buy -> Buy |
| 2025-10-17 | Keybanc | Maintains | Overweight -> Overweight |
| 2025-10-16 | Baird | Initiate | Outperform |
| 2025-10-13 | Morgan Stanley | Maintains | Equal-Weight -> Equal-Weight |
| 2025-09-03 | Needham | Reiterate | Buy -> Buy |
| 2025-08-08 | Cantor Fitzgerald | Maintains | Overweight -> Overweight |
| 2025-08-08 | Needham | Maintains | Buy -> Buy |
| 2025-08-08 | Keybanc | Maintains | Overweight -> Overweight |
| 2025-08-05 | Stifel | Maintains | Buy -> Buy |
| 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 244.592M 15.92% | 436.214M 78.34% | 601.799M 37.96% | 882.43M 46.63% | 1.248B 41.43% | 1.674B 34.13% | 1.946B 16.25% | 2.576B 32.37% | 3.774B 46.51% | 5.004B 32.59% | 6.249B 24.88% | |
| EBITDA YoY % growth | -148.174M -41.59% | -156.146M -5.38% | -184.903M -18.42% | -31.988M 82.70% | 163.44M 610.94% | 294.82M 80.38% | 510.51M 73.16% | 807.84M 58.24% | 1.027B 27.13% | N/A | N/A | |
| EBIT YoY % growth | -177.918M -32.18% | -189.801M -6.68% | -228.838M -20.57% | -134.754M 41.11% | 40.816M 130.29% | 197.61M 384.15% | 326.4M 65.17% | 835.58M 156.00% | 1.243B 48.76% | 1.684B 35.48% | N/A | |
| Operating Margin | -72.74% | -43.51% | -38.03% | -15.27% | 3.27% | 11.80% | 16.77% | 32.44% | 32.94% | 33.65% | N/A | |
| EPS YoY % growth | -0.38 -52.00% | -0.37 2.63% | -0.37 | -0.27 27.69% | 0.05 119.06% | 0.23 357.14% | N/A | N/A | N/A | N/A | N/A |
All data in USD
| Q1 / 26 | Q2 / 26 | Q3 / 26 | Q4 / 26 | Q1 / 27 | Q2 / 27 | Q3 / 27 | Q4 / 27 | |
|---|---|---|---|---|---|---|---|---|
| EPS Q2Q % growth | -0.08 29.53% | -0.07 47.98% | -0.05 -78.30% | -0.03 61.34% | -0.03 69.84% | -0.01 92.46% | 0.00 100.00% | 0.02 158.63% |
| Revenue Q2Q % growth | 194.76M 58.90% | 208.32M 44.17% | 221.13M 42.59% | 244.76M 36.24% | 265.32M 36.23% | 295.78M 41.98% | 297.82M 34.68% | 317.75M 29.82% |
| EBITDA Q2Q % growth | -24.848M 50.78% | -12.505M 70.35% | -5.09M 82.91% | 11.989M 268.69% | 16.002M 164.40% | 31.4M 351.10% | 37.006M 827.04% | 48.751M 306.63% |
| EBIT Q2Q % growth | -48.211M 18.55% | -36.338M 39.07% | -26.796M 54.56% | -16.261M 68.14% | -8.967M 81.40% | -2.441M 93.28% | 2.547M 109.51% | 12.692M 178.05% |
All data in USD
26 analysts have analysed RKLB and the average price target is 87.71 USD. This implies a price increase of 22.03% is expected in the next year compared to the current price of 71.875.
The consensus EPS estimate for the next earnings of ROCKET LAB CORP (RKLB) is -0.08 USD and the consensus revenue estimate is 194.76M USD.
The consensus rating for ROCKET LAB CORP (RKLB) is 80 / 100 . This indicates that analysts generally have a positive outlook on the stock.